HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

David R Gastfriend Selected Research

Naltrexone (ReVia)

5/2017Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.
5/2015Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
4/2015Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up.
8/2014Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
9/2013Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
10/2011Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
8/2011Injectable extended-release naltrexone for opioid dependence.
6/2011Cost and utilization outcomes of opioid-dependence treatments.
4/2011Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.
3/2011Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


David R Gastfriend Research Topics

Disease

14Alcoholism (Alcohol Abuse)
08/2014 - 04/2005
10Opioid-Related Disorders (Opiate Addiction)
05/2017 - 01/2011
4Substance-Related Disorders (Drug Abuse)
05/2017 - 01/2010
3Cocaine-Related Disorders (Cocaine Addiction)
11/2004 - 06/2002
1Alcohol-Related Disorders
06/2010
1Acute Pain
06/2008
1Medically Unexplained Symptoms
07/2005
1Tardive Dyskinesia
09/2002
1Seizures (Absence Seizure)
09/2002
1Dyspnea (Shortness of Breath)
09/2002
1Diabetes Mellitus
09/2002
1Dyskinesias (Dyskinesia)
09/2002
1Hyperventilation
09/2002
1Hypotension (Low Blood Pressure)
09/2002
1Neuroleptic Malignant Syndrome
09/2002

Drug/Important Bio-Agent (IBA)

19Naltrexone (ReVia)FDA LinkGeneric
05/2017 - 04/2005
7Opioid Analgesics (Opioids)IBA
05/2017 - 06/2008
3Methadone (Dolophine)FDA LinkGeneric
05/2015 - 06/2011
3Pharmaceutical PreparationsIBA
09/2013 - 07/2003
3Narcotic Antagonists (Opioid Antagonists)IBA
04/2011 - 04/2005
3Cocaine (Cocaine HCl)IBA
11/2004 - 06/2002
2Buprenorphine (Subutex)FDA LinkGeneric
05/2015 - 06/2011
2Delayed-Action PreparationsIBA
04/2011 - 06/2008
1Naloxone (Narcan)FDA LinkGeneric
04/2011
1EndorphinsIBA
03/2011
1vivitrolFDA Link
01/2011
1Acamprosate (Campral)FDA Link
01/2010
1Disulfiram (Antabuse)FDA Link
01/2010
1Opioid Receptors (Opioid Receptor)IBA
06/2008
1Biomarkers (Surrogate Marker)IBA
07/2005
1Antipsychotic Agents (Antipsychotics)IBA
09/2002
1Olanzapine (Zyprexa)FDA Link
09/2002

Therapy/Procedure

14Injections
05/2017 - 04/2005
7Drug Therapy (Chemotherapy)
08/2014 - 02/2006
4Therapeutics
06/2011 - 09/2002
3Ambulatory Care (Outpatient Care)
06/2011 - 01/2010